GSK Bio
NEWS
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
It’s no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.
MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.
Former founding managing director of JDRF T1D Fund joins DDF leadership team
Bittium Wearable Platform with Philips EmoGraphy & CardioSense Solution Was Awarded in the GSK’s “Transform the Future of Self-Care” Innovation Contest
Biotech and pharma companies tap new members of executive leadership teams and boards.
JOBS
IN THE PRESS